lenalidomide has been researched along with phenylethyl 3-methylcaffeate in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (phenylethyl 3-methylcaffeate) | Trials (phenylethyl 3-methylcaffeate) | Recent Studies (post-2010) (phenylethyl 3-methylcaffeate) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 10 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogan, L; Kim, MJ; Lassalle-Claux, G; Luiker, K; Murugesan, A; Reiman, T; Selka, A; Touaibia, M; Vaillancourt, E | 1 |
1 other study(ies) available for lenalidomide and phenylethyl 3-methylcaffeate
| Article | Year |
|---|---|
Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Topics: Angiogenesis Inhibitors; Apoptosis; Caffeic Acids; Cell Line, Tumor; Down-Regulation; Genes, myc; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Phenylethyl Alcohol; Sp1 Transcription Factor; Structure-Activity Relationship | 2020 |